JP2006141402A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006141402A5 JP2006141402A5 JP2006000258A JP2006000258A JP2006141402A5 JP 2006141402 A5 JP2006141402 A5 JP 2006141402A5 JP 2006000258 A JP2006000258 A JP 2006000258A JP 2006000258 A JP2006000258 A JP 2006000258A JP 2006141402 A5 JP2006141402 A5 JP 2006141402A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- antisense compound
- antisense
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000692 anti-sense effect Effects 0.000 claims description 33
- 150000001875 compounds Chemical class 0.000 claims description 33
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 108091034117 Oligonucleotide Proteins 0.000 claims description 8
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 claims description 5
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 5
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
- 238000000034 method Methods 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 11
- 102100032818 Integrin alpha-4 Human genes 0.000 description 8
- 108010041012 Integrin alpha4 Proteins 0.000 description 8
- 210000005260 human cell Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- -1 oligonucleotides Chemical class 0.000 description 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/166,203 US5968826A (en) | 1998-10-05 | 1998-10-05 | Antisense inhibition of integrin α4 expression |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000574727A Division JP3834204B2 (ja) | 1998-10-05 | 1999-08-19 | インテグリンα４発現のアンチセンス調節 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006141402A JP2006141402A (ja) | 2006-06-08 |
| JP2006141402A5 true JP2006141402A5 (enExample) | 2007-06-14 |
| JP4168285B2 JP4168285B2 (ja) | 2008-10-22 |
Family
ID=22602243
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000574727A Expired - Fee Related JP3834204B2 (ja) | 1998-10-05 | 1999-08-19 | インテグリンα４発現のアンチセンス調節 |
| JP2006000258A Expired - Fee Related JP4168285B2 (ja) | 1998-10-05 | 2006-01-04 | インテグリンα４発現のアンチセンス調節 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000574727A Expired - Fee Related JP3834204B2 (ja) | 1998-10-05 | 1999-08-19 | インテグリンα４発現のアンチセンス調節 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US5968826A (enExample) |
| EP (1) | EP1123414B1 (enExample) |
| JP (2) | JP3834204B2 (enExample) |
| AT (1) | ATE352639T1 (enExample) |
| AU (1) | AU759938B2 (enExample) |
| CA (1) | CA2345209C (enExample) |
| DE (1) | DE69934998T2 (enExample) |
| DK (1) | DK1123414T3 (enExample) |
| ES (1) | ES2279632T3 (enExample) |
| WO (1) | WO2000020635A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999060166A1 (en) * | 1998-05-21 | 1999-11-25 | Isis Pharmaceuticals, Inc. | Compositions and methods for the pulmonary delivery of nucleic acids |
| US5968826A (en) * | 1998-10-05 | 1999-10-19 | Isis Pharmaceuticals Inc. | Antisense inhibition of integrin α4 expression |
| DE19860642A1 (de) * | 1998-12-29 | 2000-07-06 | Deutsches Krebsforsch | Antisense-Oligonukleotid zur Hemmung der Expression des Adhäsionsmoleküls very late antigen 4 (VLA-4) in menschlichen Zellen |
| GB0112617D0 (en) * | 2001-05-23 | 2001-07-18 | Hoffmann La Roche | Antiviral nucleoside derivatives |
| US20030154499A1 (en) * | 2001-06-08 | 2003-08-14 | Monika Wasel-Nielen | Mouse unable to express functional alpha-4 integrin protein, and methods for assaying compounds or agents for alpha-4 integrin protein antagonist activity and a genetic marker for evaluating efficacy of modulators of signaling activity of a VLA-4 receptor |
| EP1543159A2 (en) * | 2002-08-19 | 2005-06-22 | Pharmacia Corporation | Antisense modulation of endothelial specific molecule 1 expression |
| JP2007509042A (ja) * | 2003-09-29 | 2007-04-12 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 造血前駆細胞の接着、分化および遊走を変化させるための方法 |
| US7419666B1 (en) | 2004-02-23 | 2008-09-02 | Massachusetts Eye And Ear Infirmary | Treatment of ocular disorders |
| NZ554277A (en) * | 2004-10-20 | 2010-09-30 | Antisense Therapeutics Ltd | Antisense modulation of integrin alpha 4 expression |
| US7879816B2 (en) * | 2005-06-07 | 2011-02-01 | Yale University | Methods of treating cancer and other conditions or disease states using LFMAU and LDT |
| DK2656850T3 (en) * | 2007-10-05 | 2016-11-28 | Index Pharmaceuticals Ab | Oligonucleotides for the treatment or alleviation of EDEMA |
| EP2937358B1 (en) * | 2008-06-23 | 2018-09-19 | Antisense Therapeutics Ltd | Methods for treating multiple sclerosis using antisense oligonucleotides |
| WO2012034194A1 (en) * | 2010-09-17 | 2012-03-22 | Antisense Therapeutics Ltd | Method for mobilizing stem and/or progenitor cells |
| WO2014193625A1 (en) * | 2013-05-30 | 2014-12-04 | R-Pharm Overseas, Inc. | Fully human antibodies against human receptor integrin alpha-4 |
| WO2016179634A1 (en) * | 2015-05-11 | 2016-11-17 | Murdoch University | Multiple sclerosis treatment |
| ES2938883T3 (es) * | 2015-11-05 | 2023-04-17 | Los Angeles Childrens Hospital | Oligo antisentido para su uso en el tratamiento de la leucemia mieloide aguda |
| US20200038428A1 (en) * | 2017-03-23 | 2020-02-06 | Napajen Pharma, Inc. | Cancer cell adhesion activity inhibitor |
| WO2023039643A1 (en) * | 2021-09-20 | 2023-03-23 | Antisense Therapeutics Ltd | Methods and kits therefor |
| EP4230196A1 (en) | 2022-02-21 | 2023-08-23 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of dystrophinopathies |
| CN114887034B (zh) * | 2022-07-14 | 2022-10-28 | 中山莱博瑞辰生物医药有限公司 | LLP2A-Ale在制备用于治疗和/或预防外周血淋巴细胞减少症的药物中的用途 |
| AU2023326053A1 (en) * | 2022-08-16 | 2025-03-20 | Percheron Therapeutics Ltd | Biomarkers and uses thereof in diagnosis and treatment of neurological post acute sequelae of covid 19 (npasc) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5696248A (en) * | 1994-06-15 | 1997-12-09 | Hoechst Aktiengesellschaft | 3'-modified oligonucleotide derivatives |
| US5968826A (en) * | 1998-10-05 | 1999-10-19 | Isis Pharmaceuticals Inc. | Antisense inhibition of integrin α4 expression |
-
1998
- 1998-10-05 US US09/166,203 patent/US5968826A/en not_active Expired - Lifetime
-
1999
- 1999-08-19 AU AU55703/99A patent/AU759938B2/en not_active Ceased
- 1999-08-19 JP JP2000574727A patent/JP3834204B2/ja not_active Expired - Fee Related
- 1999-08-19 DK DK99942290T patent/DK1123414T3/da active
- 1999-08-19 ES ES99942290T patent/ES2279632T3/es not_active Expired - Lifetime
- 1999-08-19 US US09/377,309 patent/US6258790B1/en not_active Expired - Lifetime
- 1999-08-19 AT AT99942290T patent/ATE352639T1/de not_active IP Right Cessation
- 1999-08-19 EP EP99942290A patent/EP1123414B1/en not_active Expired - Lifetime
- 1999-08-19 DE DE69934998T patent/DE69934998T2/de not_active Expired - Lifetime
- 1999-08-19 WO PCT/US1999/018796 patent/WO2000020635A1/en not_active Ceased
- 1999-08-19 CA CA2345209A patent/CA2345209C/en not_active Expired - Fee Related
-
2006
- 2006-01-04 JP JP2006000258A patent/JP4168285B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006141402A5 (enExample) | ||
| TWI811238B (zh) | 用於抑制脂蛋白元C-III(APOC3)表現之RNAi試劑及組合物 | |
| TWI823866B (zh) | 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法 | |
| JP7007304B2 (ja) | Ｂ型肝炎感染症治療用のＰＡＰＤ５又はＰＡＰＤ７のｍＲＮＡ減少用核酸分子 | |
| JP2024009262A (ja) | Ｌｐａの遺伝子発現の阻害のための組成物及び方法 | |
| JP7348922B2 (ja) | Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子 | |
| JP2016530882A5 (enExample) | ||
| JP2019014733A (ja) | Ｔｎｆスーパーファミリー受容体に対するスプライス切替オリゴマーならびに疾病治療における該オリゴマーの使用 | |
| US12104154B2 (en) | Antisense oligonucleic acid | |
| JP2018150344A5 (enExample) | ||
| TW202307207A (zh) | 用於抑制黃嘌呤脫氫酶(XDH)之表現之RNAi藥劑、其醫藥組合物及使用方法 | |
| RS61528B1 (sr) | Oligonukleotidi za smanjenje ekspresije pd-l1 | |
| JP2004513626A5 (enExample) | ||
| RU2010116994A (ru) | Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4) | |
| EP3790971A1 (en) | Oligonucleotides for modulating myh7 expression | |
| CN104540527A (zh) | Mir-15微小rna家族的抑制剂 | |
| US20220226361A1 (en) | Compositions and Methods for Modulating MECP2 Expression | |
| JP2011505798A5 (enExample) | ||
| JP6875684B2 (ja) | 筋萎縮症治療用アンチセンス核酸 | |
| US20190345496A1 (en) | Antisense oligonucleotides for modulating relb expression | |
| TW202200162A (zh) | 誘導外顯子５１跳讀的反義核酸 | |
| WO2020136125A2 (en) | Antisense oligonucleotides targeting card9 | |
| JP2004503246A5 (enExample) | ||
| US20200216845A1 (en) | Antisense oligonucleotides for modulating rela expression | |
| US20190367920A1 (en) | Antisense oligonucleotides for modulating nfkb1 expression |